➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Mallinckrodt
Moodys
Merck
AstraZeneca

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

Fulvestrant - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

What are the generic sources for fulvestrant and what is the scope of patent protection?

Fulvestrant is the generic ingredient in two branded drugs marketed by Astrazeneca, Accord Hlthcare, Amneal, Apotex, Chia Tai Tianqing, Dr Reddys, Eugia Pharma, Glenmark Pharms Inc, Hbt Labs Inc, Sagent Pharms Inc, Sandoz Inc, Xiromed, Zydus Pharms, Fresenius Kabi Usa, and Teva Pharms Usa Inc, and is included in fifteen NDAs. There are seven patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Fulvestrant has seventy-one patent family members in forty countries.

There are twelve drug master file entries for fulvestrant. Sixteen suppliers are listed for this compound.

Drug Prices for fulvestrant

See drug prices for fulvestrant

Recent Clinical Trials for fulvestrant

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Epizyme, Inc.Phase 2
Guangdong Women and Children HospitalPhase 2
Prisma Health-UpstatePhase 2

See all fulvestrant clinical trials

Paragraph IV (Patent) Challenges for FULVESTRANT
Tradename Dosage Ingredient NDA Submissiondate
FASLODEX INJECTABLE;INTRAMUSCULAR fulvestrant 021344 2009-10-01

US Patents and Regulatory Information for fulvestrant

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa Inc FULVESTRANT fulvestrant SOLUTION;INTRAMUSCULAR 210063-001 Aug 19, 2019 RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Hbt Labs Inc FULVESTRANT fulvestrant INJECTABLE;INTRAMUSCULAR 209714-001 Nov 21, 2019 AO RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Sagent Pharms Inc FULVESTRANT fulvestrant INJECTABLE;INTRAMUSCULAR 205871-001 Aug 22, 2019 AO RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Fresenius Kabi Usa FULVESTRANT fulvestrant SOLUTION;INTRAMUSCULAR 210326-001 May 20, 2019 RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for fulvestrant

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca FASLODEX fulvestrant INJECTABLE;INTRAMUSCULAR 021344-001 Apr 25, 2002 ⤷  Free Forever Trial ⤷  Free Forever Trial
Astrazeneca FASLODEX fulvestrant INJECTABLE;INTRAMUSCULAR 021344-001 Apr 25, 2002 ⤷  Free Forever Trial ⤷  Free Forever Trial
Astrazeneca FASLODEX fulvestrant INJECTABLE;INTRAMUSCULAR 021344-001 Apr 25, 2002 ⤷  Free Forever Trial ⤷  Free Forever Trial
Astrazeneca FASLODEX fulvestrant INJECTABLE;INTRAMUSCULAR 021344-001 Apr 25, 2002 ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for fulvestrant

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0138504 2004C/004 Belgium ⤷  Free Forever Trial PRODUCT NAME: FULVESTRANT; REGISTRATION NO/DATE: EU/1/03/269/001 20040311
0138504 SPC/GB04/009 United Kingdom ⤷  Free Forever Trial PRODUCT NAME: FULVESTRANT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/03/269/001 20040310
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Mallinckrodt
Moodys
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.